{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:38:09Z","timestamp":1787564289423,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ahj.2020.03.018","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T02:32:33Z","timestamp":1585103553000},"page":"69-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation"],"prefix":"10.1016","volume":"225","author":[{"given":"Ganesan","family":"Karthikeyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mpiko","family":"Ntsekhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Benz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumathy","family":"Rangarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayle","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjib Kumar","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathi","family":"Maklady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Eldin","family":"Elghamrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawar","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tantchou T J","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Dayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma","family":"Changsheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard M","family":"Gitura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Avezum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesl","family":"Zuhlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lwabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Haileamlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okechukwu","family":"Ogah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilly","family":"Chillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Paniagua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"ElSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Dans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Gondwe-Chunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onkabetse Julia","family":"Molefe-Baikai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus A","family":"Gonzalez-Hermosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertino","family":"Damasceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel R","family":"Kamanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Musuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairat","family":"Davletov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongani M","family":"Mayosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10142","key":"10.1016\/j.ahj.2020.03.018_bb0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(18)30999-1","article-title":"Acute rheumatic fever","volume":"392","author":"Karthikeyan","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ahj.2020.03.018_bb0010","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJMoa1603693","article-title":"Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015","volume":"377","author":"Watkins","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ahj.2020.03.018_bb0015","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCULATIONAHA.116.024769","article-title":"Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries: Two-Year Follow-Up of the Global Rheumatic Heart Disease Registry (the REMEDY Study)","volume":"134","author":"Zuhlke","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.03.018_bb0020","series-title":"M. O. Neglected disease research and development: a pivotal moment for global health","author":"Chapman","year":"2016"},{"issue":"8","key":"10.1016\/j.ahj.2020.03.018_bb0025","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.ahj.2020.03.018_bb0030","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly","volume":"147","author":"Wolf","year":"1987","journal-title":"The Framingham Study Arch Intern Med"},{"issue":"12","key":"10.1016\/j.ahj.2020.03.018_bb0035","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9921","key":"10.1016\/j.ahj.2020.03.018_bb0040","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ahj.2020.03.018_bb0045","doi-asserted-by":"crossref","first-page":"885","DOI":"10.7326\/0003-4819-128-11-199806010-00001","article-title":"Predictors of systemic embolism in patients with mitral stenosis. A prospective study","volume":"128","author":"Chiang","year":"1998","journal-title":"Ann Intern Med"},{"issue":"5392","key":"10.1016\/j.ahj.2020.03.018_bb0050","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1136\/bmj.1.5392.1209","article-title":"Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease","volume":"1","author":"Szekely","year":"1964","journal-title":"Br Med J"},{"issue":"8","key":"10.1016\/j.ahj.2020.03.018_bb0055","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.hrthm.2019.01.024","volume":"16","author":"January","year":"2019","journal-title":"Heart Rhythm"},{"issue":"36","key":"10.1016\/j.ahj.2020.03.018_bb0060","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ahj.2020.03.018_bb0065","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.chest.2017.03.048","article-title":"The global burden of atrial fibrillation and stroke: a systematic review of the clinical epidemiology of atrial fibrillation in Asia","volume":"152","author":"Bai","year":"2017","journal-title":"Chest"},{"issue":"18","key":"10.1016\/j.ahj.2020.03.018_bb0070","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehu449","article-title":"Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study)","volume":"36","author":"Zuhlke","year":"2015","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ahj.2020.03.018_bb0075","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2020.03.018_bb0080","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ahj.2012.01.003","article-title":"Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study","volume":"163","author":"Karthikeyan","year":"2012","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.ahj.2020.03.018_bb0085","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005835","article-title":"Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis","volume":"6","author":"Pan","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"47","key":"10.1016\/j.ahj.2020.03.018_bb0090","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ahj.2020.03.018_bb0095","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.ijcard.2013.01.184","article-title":"Review of epidemiology and management of atrial fibrillation in developing countries","volume":"167","author":"Nguyen","year":"2013","journal-title":"Int J Cardiol"},{"issue":"9745","key":"10.1016\/j.ahj.2020.03.018_bb0100","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.03.018_bb0105","series-title":"The Sustainable Development Goals Report 2018","author":"Economic UNDo","year":"2018"},{"issue":"8","key":"10.1016\/j.ahj.2020.03.018_bb0110","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ahj.2020.03.018_bb0115","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","article-title":"Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 Trial","volume":"69","author":"De Caterina","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2020.03.018_bb0120","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","article-title":"Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)","volume":"134","author":"Ezekowitz","year":"2016","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320300958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320300958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:03:57Z","timestamp":1757570637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320300958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":24,"alternative-id":["S0002870320300958"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.03.018","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}